Biden Team to Help AstraZeneca Find U.S. Plant After Mixup (1)

April 5, 2021, 9:36 PM

President Joe Biden’s administration is working with AstraZeneca Plc to find new manufacturing capacity in the U.S. after the company agreed to abandon a Baltimore Covid-19 vaccine plant that will focus exclusively on making doses for Johnson & Johnson.

The talks are the latest development after an error at the Emergent BioSolutions Inc. facility -- in which ingredients for the two companies’ vaccines were mixed up -- led to a batch of 15 million doses worth of drug substance being spoiled.

J&J announced Saturday that it had taken over production of its vaccine at the Emergent facility, which was ...

To read the full article log in.

Learn more about a Bloomberg Law subscription